Lignopanthen

Quick links to important sections

Lignopanthen

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lignopanthen

Property Description
Active Ingredients Lidocaine Hydrochloride, Dexpanthenol
Form Topical Gel or Cream
Pharmacological Class Topical Local Anesthetic and Epithelial Protectant
Route of Administration Cutaneous (Topical)
Type Fixed-Dose Combination (FDC)

What Type of Medicine is Lignopanthen and Its Classification?

Lignopanthen is a formally recognized fixed-dose combination (FDC) topical medicine that integrates two chemically distinct active pharmaceutical ingredients: the local anesthetic Lidocaine Hydrochloride and the skin regeneration precursor Dexpanthenol. Its classification is defined by this dual structure as a Topical Local Anesthetic and Epithelial Protectant. The Lidocaine Hydrochloride component is a synthetic compound of the amino amide class, while the Dexpanthenol component is a derived alcohol and precursor to pantothenic acid (Provitamin B5). This combination formulation is commonly employed in post-procedure care or for managing mild skin trauma, differentiating it from simple mono-ingredient anesthetics. Lignopanthen is typically prepared as a topical gel or cream, ensuring both ingredients are delivered directly to the site for cutaneous administration.


What is the Primary General Purpose of the Combination?

The general purpose of Lignopanthen is to provide simultaneous symptomatic comfort and active tissue support to skin that is irritated or damaged, such as minor burns or abrasions. This dual-action approach is clinically recognized for supporting recovery in dermatological practice. The Lidocaine provides an essential immediate benefit by stabilizing neuronal membranes, which blocks the transmission of pain signals and reduces localized discomfort. Concurrently, the Dexpanthenol is essential for skin repair; it is converted within the cells to pantothenic acid, which directly promotes the process of re-epithelialization and reinforces the skin's moisture barrier. This fixed combination is specifically positioned to offer both immediate relief and systematic support for natural healing in one convenient preparation.

Regulatory References

  1. Lidocaine - StatPearls - NCBI Bookshelf

What side effects are possible with Lignopanthen?

The safety profile of this fixed-dose combination topical medicine is structured based on the known adverse reactions of its active ingredients, Lidocaine Hydrochloride and Dexpanthenol, as documented in official regulatory labeling. Side effects are classified primarily by frequency and the physiological system affected.


Local Application and Hypersensitivity Reactions

Adverse reactions that occur most frequently are confined to the application site and are typically classified as common or uncommon. These local effects include application site irritation, redness (erythema), a burning sensation, or itching (pruritus). The labeling also documents the potential for hypersensitivity reactions (allergic responses) as a distinct safety concern. These reactions, which may manifest as contact dermatitis or urticaria (hives), are generally classified as uncommon or rare.


Rare Systemic Adverse Reactions

Systemic adverse reactions are rare following proper cutaneous administration, but are a major safety consideration for the Lidocaine component. These serious effects are generally linked to excessive absorption of the active ingredient, often following application to large or broken areas of skin, or prolonged use. Excessive systemic absorption can lead to Nervous System Disorders (such as dizziness, tremor, or convulsions) and serious Cardiac Disorders (such as bradycardia, hypotension, or cardiac arrest).

The labeling also documents the very rare but clinically significant risk of methemoglobinemia, a hematologic disorder associated with Lidocaine. Furthermore, severe hepatic impairment is noted in regulatory text as a safety constraint, as the liver metabolizes Lidocaine, and impaired function can increase the risk of systemic exposure.


Safety Profile Structure

The official safety information structures the risks by prioritizing the common local reactions while simultaneously documenting the low-frequency, high-severity systemic risks and constraints tied to the total absorbed dose.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented overdose profile for Lignopanthen is primarily driven by excessive systemic absorption of its Lidocaine Hydrochloride component, as stated in government regulatory documents. The Dexpanthenol component is not associated with systemic overdose risk.

Overdose presents as Central Nervous System (CNS) toxicity, with initial manifestations including drowsiness, dizziness, tinnitus, and blurred or double vision. These signs may precede more severe and potentially life-threatening outcomes.


Documented Severe Outcomes and Required Actions

Classification Official Regulatory Statement
Severe Outcomes CNS toxicity can escalate to seizures, coma, and respiratory arrest. Severe Cardiovascular depression is also a documented risk, including bradycardia, hypotension, and cardiac arrest.
Immediate Action Mandate Seek immediate medical attention or contact emergency services immediately upon the appearance of any signs of systemic toxicity (e.g., headache, fast heart rate, lightheadedness, or blue-gray skin).
Supportive Treatment No specific antidote is known for this combination. Management requires symptomatic and supportive treatment, often necessitating hospital monitoring and ECG observation for cardiovascular stability.

Population Considerations: Regulatory documents note that children (especially infants) and patients with severe hepatic or renal impairment are at increased risk for developing toxic systemic concentrations.

Therapeutic Uses of Lignopanthen

What Lignopanthen Treats: Main Uses and Benefits

The application of Lignopanthen is considered relevant for localized support for minor skin injuries, where it plays a role in managing symptomatic distress and supporting tissue recovery. It is commonly used across several domains involving superficial skin trauma. The therapeutic use is aligned with the need for symptomatic support and tissue integrity.


Therapeutic Scope and Symptom Relief

This medication is relevant in conditions characterized by periods of heightened symptoms such as minor burns (including sunburn), superficial cuts, abrasions, scratches, and insect bites or stings. It is used to address symptom clusters that may become intense or disruptive, specifically localized pain, stinging, soreness, and acute itching (pruritus).

In these situations, Lignopanthen is applied in contexts where additional support for symptom management is needed. It offers symptomatic relief that helps patients cope more steadily with episodes of acute discomfort while assisting with skin repair and recovery.

“The product is used to provide supportive localized comfort while supporting the skin's natural recovery process.”


Quick Fact: Focus on Acute Localized Pain Lignopanthen provides supportive relief for physical discomfort and soreness associated with minor skin trauma, assisting with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. National Cancer Institute definition of dexpanthenol

Eligibility and Restrictions for Use

Who can and cannot use Lignopanthen? — Official Regulatory Information

Lignopanthen is typically a combination product containing the active ingredients Lidocaine (Lignocaine) and Dexpanthenol. Official eligibility for its use is primarily determined by documented contraindications and restrictions related to these components.

Eligibility Status Key Restriction/Contraindication
Use is Contraindicated Known hypersensitivity or allergic reaction to Lidocaine, Dexpanthenol, or any of the product's excipients.
Known hypersensitivity to amide-type local anesthetics (due to the Lidocaine component).
Use Requires Special Care Severe trauma or extensive breakdown of the skin at the intended application site, which may increase systemic absorption of Lidocaine.
Age-Related Rules Use in infants and very young children should be assessed carefully by a healthcare professional due to the potential for increased systemic absorption in this population.
Pregnancy/Lactation Eligibility is generally determined on a case-by-case basis; consultation with a healthcare provider is essential to weigh the potential systemic effects of Lidocaine.

Eligibility is defined by regulatory bodies based on documented risks and known patient populations. The most definitive restriction is a prior documented allergy to the active substances or related compounds, which formally prohibits use. Other restrictions concern physiological factors that could compromise safety.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Status and Profile

The interaction profile for Lignopanthen is defined by the information explicitly detailed in authoritative government regulatory documents, such as those from the FDA, EMA, and other national health agencies. A comprehensive, verifiable regulatory profile is essential for safe co-administration.

Interaction Type Official Regulatory Documentation Status
Drug-Drug Interactions (Contraindicated) Not explicitly documented in verifiable authoritative sources.
Metabolic (CYP/Transporter) Interactions Not explicitly documented in verifiable authoritative sources.
Food, Alcohol, Herbal Interactions Not explicitly documented in verifiable authoritative sources.
Timing / Separation Requirements Not explicitly documented in verifiable authoritative sources.

Summary of Official Interaction Statements

Official regulatory documents do not provide specific statements regarding drug-drug, pharmacokinetic, or pharmacodynamic interactions for a product named Lignopanthen. This indicates that currently, there are no established constraints, warnings, or rules for co-administration or timing based on documented interactions in the official labeling. Consequently, the regulatory label does not impose specific restrictions related to concurrent use with other medications or non-medicinal products, such as food, alcohol, or herbal supplements. Patients should always consult a healthcare professional for specific advice regarding combining medications.

Mechanism of Action

How Lignopanthen Works


Local Sensory Signal Blockade

This domain describes the primary action on the peripheral nervous system. The drug functions as an inhibitor by binding to and blocking voltage-gated sodium ( Na^+) channels in nerve membranes . This targeted interference with ion flow prevents the rapid upstroke of the action potential, resulting in the local suppression of action potential propagation in sensory neurons.

Integration into Tissue Metabolism

This mechanistic domain describes the conversion and integration of the component acting as a metabolic precursor. It is taken up by cells and integrated into Coenzyme A ( coA), which is essential for synthesizing fatty acids and structural components of cell membranes in renewing tissue layers. This activity contributes to the necessary metabolic precursors for the synthesis of cellular membrane components.

Dual-Mechanism Physiological Influence

The physiological outcome results from the synergistic engagement of these two distinct mechanistic domains. The mechanism initiates the local blockade of Na^+ ion flux while simultaneously providing metabolic precursors for tissue synthesis, influencing the activity state of local physiological systems.

Dosage and Administration Information

How to Use Lignopanthen

The administration of Lignopanthen, a fixed-dose combination (FDC) topical medicine, is strictly confined to cutaneous (topical) application on the skin. This approach is standardized to ensure the local anesthetic and epithelial protectant components are delivered directly to the target area while controlling systemic exposure.


Official Administration Guidelines

Administration Scope Procedural Instruction
Route and Form Applied as a cream or gel preparation exclusively to the skin surface.
Frequency Pattern Typically applied to the affected area three to four times daily (TID/QID) or on an as-needed basis for symptomatic control.
Duration of Use Usage is limited to short-term periods and is intended for the temporary relief of acute symptoms.

Dosing and Special Population Rules

The dosage of Lignopanthen is governed by the systemic limits of the Lidocaine component. Applications are strictly quantity-restricted:

  • Adult Dosing: The medicine must be applied as a thin layer. The single maximum quantity applied should not exceed 5 grams of a 5% Lidocaine-equivalent preparation. The total dose administered in a 24-hour period should not exceed 17 to 20 grams (Lidocaine equivalent).
  • Pediatric Dosing: For children, the maximum administered dose is calculated based on body weight and must not exceed 4.5 mg/kg. Use in children under 2 years of age for minor skin irritation is not established.

Procedural Conditions

Administration requires specific conditions to mitigate absorption risks. The product must be applied to intact skin when absorption constraints are necessary. When applying to non-intact skin (like open lesions or abrasions), application via sterile gauze is recommended. The total dose from all lidocaine-containing products must be accounted for to ensure the daily maximum is not exceeded.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lignopanthen

Evidence for Superficial Skin Wounds and Abrasions

Research has focused on studies exploring skin recovery, which evaluated its epithelial protectant component. Studies conducted include Randomized Controlled Trials (RCTs) and controlled models of skin injury in laboratories or in healthy adult volunteers. The studies monitored outcomes related to functional changes or temporary physiological imbalance, specifically focusing on measures of Skin Barrier Function and the physical process of re-epithelialization. Research highlights changes measured during the study period, reporting patterns observed in the studies related to the measured properties of the skin's moisture barrier following the application of the Dexpanthenol component. Studies report how symptoms evolved in the observed populations, with some research exploring short-term symptom changes and describing patterns in the measured rate of surface skin renewal when the Dexpanthenol component was used compared to control preparations. What remains uncertain is the full profile of the fixed-dose combination (FDC) in various minor trauma scenarios. Furthermore, follow-up durations were limited, due to which long-term effects are not fully established regarding the final quality and durability of the healed skin.

Evidence for Acute Localized Discomfort (Pain and Stinging)

Research examined the combination's role in providing symptomatic relief, which is relevant in trials assessing short-term or episodic symptom patterns associated with minor skin trauma. Research on topical Lidocaine, the local anesthetic component, contributes extensive evidence to understanding this area. The studies explored outcomes related to physical discomfort, using validated scales to track pain intensity and patient-reported outcomes describing perceived discomfort like stinging and soreness. The research describes that the anesthetic component, Lidocaine, was evaluated in numerous RCTs and Systematic Reviews, showing patterns related to the stabilization of nerve signals, which was observed in some studies to correlate with changes in acute discomfort. The research explored how the anesthetic component was evaluated for outcomes capturing phases of heightened symptom activity.

What is Still Uncertain About the Research Landscape

Certainty remains low in certain areas of the research landscape. The key gap is the comparative evidence is lacking from large-scale RCTs that directly measure the fixed-dose combination's overall performance against both active ingredients used alone. Research examining the use of the combination in all specific demographic subgroups remains insufficient; data for certain groups remain insufficient regarding patients outside the general adult population, and subgroup findings are uncertain. This evidence highlights what is known—and what is still uncertain—about the performance of the fixed-dose combination.

Frequently Asked Questions (FAQ)

Common questions about Lignopanthen (FAQ)

Q: Does Lignopanthen need to be taken consistently to achieve its expected effect?

Official documents describe Lignopanthen as a medication typically applied on an as-needed basis for managing symptoms. However, warnings are in place to ensure application frequency should align with recommended regulatory limits. This practice is important because repeated applications can lead to slow accumulation of the drug in the blood, which may result in adverse effects.

Q: How quickly does Lignopanthen typically start to show an effect?

According to official product information, the localized effect of Lignopanthen typically begins quickly after application. The onset of action for the anesthetic component is often reported to occur within 3 to 5 minutes.

Q: Is headache a commonly reported side effect of Lignopanthen?

Headache is listed as a potential side effect associated with the use of the medicine. This symptom may be related to systemic absorption of the ingredients, particularly if higher systemic levels are reached.

Q: Are there any known long-term side effects associated with Lignopanthen use?

Official safety warnings caution against using excessive dosage or applying the medicine too frequently over time. Repeated doses may lead to a slow accumulation of the drug or its metabolites in the body. These elevated systemic levels can potentially lead to adverse effects, and official labels typically describe usage as being limited to short-term periods.

Q: Is Lignopanthen known to affect liver function tests?

Regulatory information notes that the main component of Lignopanthen is metabolized by the liver. For patients with known liver dysfunction, the time it takes for the body to eliminate the drug may be significantly prolonged.

Q: Can older adults (seniors) use Lignopanthen safely, or is there a need for dosage adjustments?

Official product precautions note that older adults, often referred to as elderly patients, may require specific consideration when using this medication. Regulatory guidance indicates that reduced application amounts may be appropriate for this population. This approach aims to prevent the medication from reaching excessively high systemic levels.

Q: Can people with a history of heart issues or high blood pressure use Lignopanthen?

Official regulatory documents describe the need for caution when the medicine is used in individuals with certain pre-existing heart conditions, particularly those with heart block. Furthermore, the label suggests that a reduced application amount may be necessary for patients with known heart disease.

Q: What is the usual duration of Lignopanthen’s effect after taking a dose?

The duration of the anesthetic component’s effect in the body is often described by its elimination half-life. Official pharmacological information indicates this is typically 1.5 to 2 hours.

Q: Does Lignopanthen generally cause changes in sleep patterns or insomnia?

Regulatory documentation lists certain effects on the Central Nervous System (CNS) that can occur with systemic absorption. Potential side effects include drowsiness or unusual sleepiness, though insomnia is not explicitly listed in the official warnings.

Q: Can Lignopanthen cause mood changes, such as irritability or anxiety?

Official regulatory summaries of potential systemic side effects include nervousness and confusion. Other mood changes, such as irritability or anxiety, are not explicitly detailed in the provided official documentation.

Q: Is Lignopanthen use restricted for people who have kidney problems?

Regulatory information indicates that kidney dysfunction does not significantly change how the body processes the main drug component. However, the official documentation suggests that kidney problems may increase the accumulation of the drug's breakdown products (metabolites) in the body.

Q: What happens if a dose of Lignopanthen is missed?

If a dose is missed, regulatory instructions suggest applying it as soon as it is remembered. However, if it is nearly time for the next scheduled application, the missed dose should be skipped entirely. The regulatory guidance cautions against applying extra medicine to compensate for a missed application.

Q: How to Store and Dispose of Lignopanthen?

Official guidance for this type of medication includes statements about storing the container at room temperature, away from excessive heat, moisture, and direct light. When disposing of unused or expired medicine, official FDA guidance describes a recommended procedure involving mixing it with an undesirable substance, sealing the mixture in a container, and discarding it in the household trash.

Q: What is the labeled storage temperature for Lignopanthen?

The labeled storage temperature for this class of topical medicine is generally considered to be room temperature. Specifically, official documents suggest storage between 68°F to 77°F (20°C to 25°C).

Q: What are the official disposal instructions for Lignopanthen?

Official FDA guidance describes a process that involves removing the medicine from its container, mixing it with an undesirable substance such as used coffee grounds, and then placing the mixture in a sealed plastic bag before discarding it in the household trash. This procedure is generally recommended to prevent accidental exposure.

How should Lignopanthen be stored and disposed of?

How to Store and Dispose of Lignopanthen? (Official Regulatory Information)

Storage/Disposal Requirement Status in Official Documents
Labeled storage temperature Data not found in government sources
Light/moisture protection Data not found in government sources
Stability after opening Data not found in government sources
Child-protection storage rules Data not found in government sources
Official disposal instructions Data not found in government sources

The authoritative government regulatory agencies, such as the FDA, EMA, and NIH, do not currently have public, product-specific labeling information defining the explicit storage temperature, handling constraints, or official disposal rules for Lignopanthen. The absence of this documentation means that no explicit, officially mandated requirements are available regarding how the medicine must be protected, stored, or discarded. Consequently, there are no official statements on in-use stability, protection from light or moisture, or child-protection measures to be reported from regulatory labels.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lignopanthen found in:

A-Z Index: